Cargando…

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

Blinatumomab can induce a complete haematological remission in patients in 46.6% with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) resulting in a survival benefit when compared with chemotherapy. Only bone marrow blast counts before therapy have shown a weak prediction of r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duell, J, Dittrich, M, Bedke, T, Mueller, T, Eisele, F, Rosenwald, A, Rasche, L, Hartmann, E, Dandekar, T, Einsele, H, Topp, M S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629361/ https://www.ncbi.nlm.nih.gov/pubmed/28119525 http://dx.doi.org/10.1038/leu.2017.41

Ejemplares similares

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
por: Ribera, Jose-Maria, et al.
Publicado: (2020)

The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78
por: Rasche, Leo, et al.
Publicado: (2013)

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
por: Köhnke, Thomas, et al.
Publicado: (2015)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement
por: Steinhardt, Maximilian J., et al.
Publicado: (2021)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
por: Semchenkova, Alexandra, et al.
Publicado: (2022)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
por: Nägele, Virginie, et al.
Publicado: (2017)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
por: Pulte, E. Dianne, et al.
Publicado: (2018)

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Stein, Anthony, et al.
Publicado: (2018)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
por: Topp, Max S., et al.
Publicado: (2021)

Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3(+) regulatory T cells in humans and mice
por: Bedke, Tanja, et al.
Publicado: (2014)

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
por: Mejstríková, E., et al.
Publicado: (2017)

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Blinatumomab-associated vasculitis
por: Liau, MeiQi May, et al.
Publicado: (2017)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2021)

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
por: Sigmund, Audrey M, et al.
Publicado: (2020)

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
por: Zugmaier, G, et al.
Publicado: (2014)

Blinatumomab-induced T cell activation at single cell transcriptome resolution
por: Huo, Yi, et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
por: Gökbuget, Nicola, et al.
Publicado: (2020)

Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
por: Caillon, Megane, et al.
Publicado: (2023)

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
por: Locatelli, Franco, et al.
Publicado: (2020)

Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2021)

Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival
por: Blenk, S., et al.
Publicado: (2007)

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
por: Delea, Thomas E., et al.
Publicado: (2019)

Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab
por: Mikhailova, Ekaterina, et al.
Publicado: (2020)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience
por: Duminuco, Andrea, et al.
Publicado: (2023)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
por: Topp, Max S., et al.
Publicado: (2020)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
por: Lee, Kum Ja, et al.
Publicado: (2016)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
por: Wu, Shang-Ju, et al.
Publicado: (2023)

Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab
por: Abdo, Yasmeen, et al.
Publicado: (2023)

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Bonifacio, Massimiliano, et al.
Publicado: (2022)

Identifying functional modules in protein–protein interaction networks: an integrated exact approach
por: Dittrich, Marcus T., et al.
Publicado: (2008)

PB1738: OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B – ALL WITH INVALID OR RECURRENT CART
por: Yuehui, Lin
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1j6p2pvl44keqvffumnbiprhth